These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 5072392

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Levodopa and Ro 4-4602 in psoriasis.
    Giroux JM, Dubuc R, Barbeau A.
    Lancet; 1972 Aug 12; 2(7772):333-4. PubMed ID: 4115065
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A, Mars H, Botez MI, Joubert M.
    Can Med Assoc J; 1972 Jun 10; 106(11):1169-74. PubMed ID: 5034697
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Effect of VB6 on L-DOPA decarboxylase activity in the organs of rats given peripheral L-DOPA decarboxylase inhibitors (author's transl)].
    Yoshimine N, Kuzuya F, Mori K, Sakamoto N.
    Nihon Ronen Igakkai Zasshi; 1978 Nov 10; 15(6):566-73. PubMed ID: 732010
    [No Abstract] [Full Text] [Related]

  • 29. [Symposium: metabolism in neurological disorders. 1. Parkinsonism. 1-(2). Dopamin metabolism in urine and brain of patients with parkinsonism, with special reference to vitamin B 6 and L-DOPA-treatment].
    Kuzuya F, Wakita T, Kawahara H.
    Nihon Naika Gakkai Zasshi; 1972 Sep 10; 61(9):1131-5. PubMed ID: 4674039
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Drug-induced changes in brain dopamine and their relation to parkinsonism.
    Vogt M.
    Sci Basis Med Annu Rev; 1970 Sep 10; ():276-91. PubMed ID: 4319923
    [No Abstract] [Full Text] [Related]

  • 32. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
    Johnson RD, Ruthven CR, Goodwin BL, Sandler M.
    J Neural Transm; 1976 Sep 10; 38(3-4):181-91. PubMed ID: 956809
    [Abstract] [Full Text] [Related]

  • 33. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.
    Amino Acids; 2005 Mar 10; 28(2):157-64. PubMed ID: 15750845
    [Abstract] [Full Text] [Related]

  • 34. Treatment of Parkinsonism with L-dopa and decarboxylase inhibitors. An electrophysiological study.
    Dietrichson P.
    Acta Neurol Scand Suppl; 1972 Mar 10; 51():111-3. PubMed ID: 4514333
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Levodopa.
    Lancet; 1971 Sep 04; 2(7723):533. PubMed ID: 4105672
    [No Abstract] [Full Text] [Related]

  • 38. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R, Kvan L, Presthus J, Thoresen GB.
    Acta Neurol Scand Suppl; 1972 Sep 04; 51():121-2. PubMed ID: 4514336
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Recent advances in the treatment of Parkinsonism with drugs.
    Rinne UK.
    Acta Neurol Scand Suppl; 1972 Sep 04; 51():59-103. PubMed ID: 4576076
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.